BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition
Rare disease drug developer BioMarin Pharmaceutical is buying its way to revenue growth with a $4.8 billion deal for Amicus ...
Rare disease drug developer BioMarin Pharmaceutical is buying its way to revenue growth with a $4.8 billion deal for Amicus ...
TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates, to combat neurodegenerative diseases, today ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...
Drugs have been the standard migraine treatment for decades. The severe headaches, nausea, and other problems associated with this common ...
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to ...
Takeda Pharmaceutical is expanding its prospects in hematology with a deal for rights to a drug advancing to pivotal testing ...
Credit: PD Neurotechnology The use of PD Neurotechnology's pioneering telemonitoring device to assess Parkinson's Disease (PD) symptoms and inform medication ...
Credit: Pixabay/CC0 Public Domain Swiss pharmaceutical giant Roche said on Tuesday it agreed to buy US biopharma firm Poseida Therapeutics ...
Alector Therapeutics said Monday that its Phase 2 trial for an experimental Alzheimer’s antibody failed, dealing a blow to what ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.